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Abstract: Protozoan parasites cause serious human and zoonotic infections, including life-threatening diseases such as 
malaria, African and American trypanosomiasis, and leishmaniasis. These diseases are no more common in the developed 
world, but together they still threaten about 40% of the world population (WHO estimates). Mortality and morbidity are 
high in developing countries, and the lack of vaccines makes chemotherapy the only suitable option. However, available 
antiparasitic drugs are hampered by more or less marked toxic side effects and by the emergence of drug resistance. As 
the main prevalence of parasitic diseases occurs in the poorest areas of the world, the interest of the pharmaceutical com-
panies in the development of new drugs has been traditionally scarce. The establishment of public-private partnerships fo-
cused on tropical diseases is changing this situation, allowing the exploitation of the technological advances that took 
place during the past decade related to genomics, proteomics, and in silico drug discovery approaches. These techniques 
allowed the identification of new molecular targets that in some cases are shared by different parasites. In this review we 
outline the recent developments in the fields of protease and topoisomerase inhibitors, antimicrobial and cell-penetrating 
peptides, and RNA interference. We also report on the rapidly developing field of new vectors (micro and nano particles, 
mesoporous materials) that in some cases can cross host or parasite natural barriers and, by selectively delivering new or 
already in use drugs to the target site, minimize dosage and side effects.  
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INTRODUCTION 
  Protozoan parasitic diseases remain an unsolved public 
health problem, especially in tropical regions. The major 
death toll is due to malaria, leishmaniasis, and African and 
American trypanosomiasis, whose high mortality rates in 
developing countries are associated to poor sanitary condi-
tions and lack of efficient prophylactic measures [1]. In the 
so-called developed countries these diseases were since long 
eradicated, but some of them are reappearing as opportunis-
tic infections in immunodeficient patients or as emerging 
diseases related to tourist exchange, immigration flows from 
endemic areas and climate changes linked to global warming 
[2]. Despite the remarkable amount of research aimed at the 
production of protective vaccines, the success is still elusive 
and chemotherapy remains the mainstay for the treatment of 
these diseases. However, many of the drugs currently in use 
were introduced decades ago, and most of them suffer of 
serious disadvantages. Because the main prevalence of para-
sitic diseases occurs in the poorest areas of the world, the 
market has not enough strength to drive the development of 
new drugs. In 2000, only about 0.1% of investment in health 
research was related to malaria, leishmaniasis, trypanosomi-
asis and tuberculosis, whereas the cumulative contribution   
of these diseases to the global disease burden is 5% [1].   
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Notwithstanding these handicaps, in recent years the search 
for antiparasitic drugs received new impulse thanks to new 
technical and political developments. Among these, particu-
larly important have been the publicly-founded sequencing 
of parasitic genomes and the establishment of public-private 
partnerships focused on tropical diseases [1].  
  The studies on host-parasite interactions at the cellular 
level have been revolutionized by the use of reporter genes, 
from  -gal to luciferase and fluorescent proteins [3]. This 
technology provided new impetus to the development of 
reliable drug screens, and a WHO program for training in 
tropical diseases research has initiated a network based on 
reporter gene technology to hasten the process of drug dis-
covery [3]. The availability of the fully sequenced and as-
sembled genomes of Plasmodium, Leishmania and Trypano-
soma species provides a multidisciplinary approach based on 
structure-function studies of proteins and high-through-put 
screening of drug libraries. In theory, the possibility to com-
pare parasitic genomes and the in deep knowledge of parasite 
metabolism allow the development of new drugs that target 
biochemical processes common to different parasites. This 
strategy, when possible, would produce huge savings in the 
development, toxicity testing and marketing procedures. Ac-
cordingly, many recently established lines of research are 
primarily focused on the identification of new targets and on 
the subsequent screening of thousands of substances to find 
active molecules suitable for human therapy.  
  In this short review we will report on protease and topoi-
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proaches based on RNA interference, proteomics and nano-
drug delivery.  
PROTEASE INHIBITORS 
  Proteases, a large group of ubiquitous enzymes involved 
in a multitude of physiological reactions, ranging from pro-
tein catabolism to activation or signal functions, have re-
cently been identified as druggable targets. Many protease 
inhibitors are currently used in antiretroviral therapy and 
more are being developed to treat hypertension, diabetes, 
thrombosis, osteoporosis, infectious diseases, and cancer. 
Several proteases have also been identified as promising 
targets by genetic or chemical knock-out studies in proto-
zoan parasites [4]. As homologous proteases can perform 
similar functions in different parasites, it can be envisaged 
that in some cases a single inhibitor could be used for more 
than one disease among malaria, trypanosomiasis, leishma-
niasis, toxoplasmosis, cryptosporidiosis, and amebiasis. Pro-
tozoan proteases are involved in the cell metabolism or in the 
interaction with the host, behaving in this case as true viru-
lence factors. On this assumptions, the selective inhibition of 
crucial protozoan proteases is one of the most promising 
strategies to develop new therapies against Plasmodium, 
Leishmania and Trypanosoma. 
  Essential processes unique to the Plasmodium and not to 
the host represent good targets for new antimalarial drugs. 
The sequencing of the Plasmodium genome brought into 
light many new potential targets, that can be broadly classi-
fied into three categories: targets involved in membrane 
transport and signalling, targets involved in metabolic proc-
esses, and targets involved in protein degradation [5]. Malar-
ial proteases can be divided into two functional groups: pro-
teases involved in erythrocyte invasion and rupture, and pro-
teases involved in haemoglobin degradation [6]. Cysteine 
protease (CP) inhibitors such as the epoxysuccinyl peptide 
E64 from Aspergillus japonicum, or leupeptin (an actinomy-
cete-derived tetrapeptide) and chymostatin (a streptomycete-
derived mixture of three oligopeptides) block erythrocyte 
rupture, causing the clustering of intracellular merozoites. 
These molecules can be used as templates for the develop-
ment of new inhibitors specific to individual plasmodial pro-
teases [6]. One of the best studied plasmodial metabolic 
pathways is the process of haemoglobin degradation [7]. 
Within the intra-erythrocytic form of the parasite the haemo-
globin is degraded by papain-like CPs (falcipains) and aspar-
tic proteases (plasmepsins) to amino acids utilized by the 
parasite to grow and replicate [7]. The P. falciparum falci-
pains involved in haemoglobin catabolism (falcipain-2, fal-
cipain-2’, and falcipain 3) are recognized as promising tar-
gets of new antimalarial drugs [8]. Some compounds of the 
azadipeptide nitrile family display in vitro structure-
dependent antimalarial activity against both chloroquine-
sensitive and chloroquine resistant P. falciparum by inhibit-
ing falcipain 2 and 3 [7]. Malaria plasmepsins are responsi-
ble for the initial cleavage of haemoglobin within the food 
vacuole of the parasite during its erythrocytic stage. In P. 
falciparum there are ten different plasmepsin genes, that 
share a 65-70% sequence homology [9]. Due to this gene 
redundancy, the so far discovered single plasmepsin inhibi-
tors are not able to completely stop parasite growth, and this 
is the main reason for the delay of their development as 
drugs. To achieve parasite starvation, the ideal inhibitor 
should be simultaneously active against plasmepsins I, II, IV 
and the structurally related histo-aspartic protease HAP, but 
inactive against the most closely related human aspartic pro-
teases (cathepsins D and E), that share 35% sequence ho-
mology with parasite plasmepsins [5]. Starting from the 
three-dimensional structure of P. falciparum plasmepsin II, a 
series of compounds of the bicyclic diamine family, active 
against the above mentioned P. falciparum plasmepsins but 
inactive on human cathepsins, have been developed [10]. 
The screening and testing of new plasmepsins inhibitors is 
performed by many research teams using the most up-to date 
techniques, such as proteomics [11] or the computational in 
silico approach [5, 12, 13]. By using the proteomics ap-
proach, Liu et al. have recently identified a P. falciparum 
plasmepsin inhibitor, G16, with an IC50 value of 937.5 nM 
and no apparent cytotoxicity against common mammalian 
cell lines [11]. The inhibitory effect of this compound has 
been tested in vitro on human parasite-infected RBC. Results 
showed a dose-dependent, marked decrease in the number of 
newly formed ring-stage parasites, and at the same time an 
increase of free extracellular merozoites. These results need 
to be fully investigated prior to further development of the 
compound. 
  Proteases also play multiple roles in the pathogenesis of 
Chagas disease. The complete sequentiation of T. cruzi ge-
nome showed the presence of seventy CPs, forty serine pep-
tidases, about two hundred and fifty metallopeptidases (most 
of them presenting homology to leishmanolysin), twenty five 
threonine peptidases and two aspartic peptidases [14]. 
Among these, cruzipain, a lysosomal enzyme belonging to 
type I CPs, is the best characterized and is currently consid-
ered a relevant candidate as a drug target and as a vaccine 
component [14]. The agents of African trypanosomiases 
share a major CP termed rhodesain in T. b. rhodesiense and 
brucipain in T. b. brucei, both belonging to the cathepsin L 
subfamily of the papain-like CPs and showing a 98.4% ho-
mology in protein sequence [15]. Effective inhibitors include 
thiosemicarbazones, that have a reversible effect, and pepti-
dyl-vinyl sulfones, peptidyl-epoxychetones, and peptidyl-
epoxysuccinates that irreversibly inactivate the enzyme ac-
tive site [15]. The recently investigated aziridinyl peptides 
belonging to the family of peptidomimetic CP irreversible 
inhibitors are active against the above mentioned trypano-
some major CPs [15], plasmodial falcipain 2 [16] and 
leishmania CPs [17]. Some of these compounds are highly 
selective for cathepsin-like parasite CPs and have been 
shown to impair the in vitro growth of L. major promas-
tigotes and to decrease the infection rate of macrophages. 
Moreover, these compounds modulate cytokine secretion 
and stimulate NO production by infected macrophages [17].  
TOPOISOMERASE INHIBITORS 
  DNA topoisomerases are ubiquitous enzymes involved in 
DNA replication, transcription, recombination and repair 
processes. They can be divided into two categories: DNA 
topoisomerases type I and type II. Eukaryotic cell type I 
DNA topoisomerases are monomeric ATP-independent en-
zymes active on positively and negatively supercoiled DNA 
by introducing single-stranded breaks followed by passage 
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lently bind to the 5’ end of the broken DNA strand, and type 
IB that bind to the 3’ end. Leishmania and Trypanosoma 
type IB topoisomerases have a peculiar heterodimeric bi-
subunit structure, unique in nature, which makes them very 
attractive as drug targets [2, 18]. Type II topoisomerases are 
ATP-dependent enzymes that introduce transient double 
strand breaks in the double helix followed by passage and 
rejoining. They can also be divided into type II, with ho-
modimeric structure, and type II, with heterotetrameric 
structure [2].  
  Topoisomerase inhibitors fall into two general categories: 
compounds that stimulate the formation of covalent enzyme-
DNA complexes (topoisomerase poisons or class I inhibi-
tors), and compounds that interfere with the enzymatic func-
tions (class II inhibitors). The identification of topoi-
somerases as promising drug targets is based on the clinical 
success of camptothecin derivatives as anticancer agents. 
Camptothecin, a natural pentacyclic alkaloid obtained from 
the barks and stem of the Chinese plant Camptotheca accu-
minata, exerts a strong inhibition on a wide range of type I 
topoisomerases. The molecule as such has heavy toxic side-
effects, but it is the progenitor of a large family of anti-
tumour derivatives, some of which are currently used in anti-
cancer therapy. Camptothecin is a potent poison of P. falci-
parum and T. brucei topoisomerase IB. Two of its deriva-
tives, irinotecan and topotecan, which are in use as anti-
tumour drugs, showed a reduced cytotoxic effect against T. 
brucei trypomastigotes, probably due to low intake into the 
parasite [19]. Camptothecin has been shown to inhibit the 
growth of L. donovani promastigotes in vitro [20], and stud-
ies performed in a mouse model of visceral leishmaniasis 
showed that the i.p. administration of liposome-encapsulated 
camptothecin at a dose of 2.5 mg/kg body weight induced a 
significant reduction of the parasitic burden in spleen and 
liver [21]. Sen et al. elucidated camptothecin mechanism of 
action in L. donovani, showing that by inhibiting type IB 
topoisomerase it starts a cascade of events resulting in cellu-
lar apoptosis [22]. Some topoisomerase II inhibitors such as 
ofloxacin, m-amsacrine and DW6, a DNA quadruplex 
binder, are also active against Trichomonas vaginalis, whose 
resistance against currently used drugs is increasing world-
wide [23].  
ANTIMICROBIAL PEPTIDES 
  Antimicrobial peptides (AMPs) are evolutionary con-
served factors [24] that participate to the innate immune re-
sponse representing the first line of defence against patho-
gens, and combine antimicrobial activity with angiogenic, 
immunomodulating and anti-inflammatory properties [25]. 
The concept of using AMPs as therapeutic tools was first 
introduced in the late 1990s, however none of them has yet 
reached the market [26]. Following the discovery, some 20 
years ago, that magainins and cecropins display antiparasitic 
activities, many studies suggest that AMPs represent a prom-
ising starting point to develop new and efficient antiparasitic 
drugs [27]. Most known AMPs have been found in the skin 
of amphibians, but they are also produced by skin and mu-
cosal surfaces of mammals in response to infections. The 
AMP exact mechanism of action has yet to be established, 
but, according to the most accepted model, the initial phase 
consists in an electrostatic interaction with the target cell, 
followed by massive accumulation and insertion into the 
plasma membrane. Subsequently, cecropins and magainins 
kill microorganisms by membrane permeabilization, with a 
detergent-like effect accompanied by pore formation [28-30]. 
This mechanism is quite rapid, concentration-dependent and, 
most important, it does not need to interact with a specific 
receptor, thus avoiding the selection of resistant strains. The 
AMP specificity of action relies on the differences in the 
composition and physicochemical properties of germ and 
host cell membranes. The possibility to select resistant prote-
inase-producer strains is unlikely, due to the fast kinetics of 
the process. Protozoan resistance mechanisms could more 
probably be of the barrier type, including the ability to form 
cysts (Entamoeba, Giardia, Toxoplasma, Cryptosporidium), 
the production of glycocalix (Trypanosomatidae), and the 
suitability to intracellular parasitism (Plasmodium, Leishma-
nia, T. cruzi, Toxoplasma, Cryptosporidium). Many AMPs 
of different origin have been shown to be active against pro-
tozoa: Plasmodium falciparum is sensitive to magainin 2 and 
dermaseptin S3 and S4; T. cruzi to phylloseptin O1 and O2 
and to dermaseptin Dl1 and Dl2; C. parvum to magainin 2, 
buforin 2, and ranalexin 1CB; L. mexicana to dermaseptin 
S1; L. amazonensis to dermaseptin O1 and H3; L. major to 
skin peptide YY and to dermaseptin S1, S4 and to their syn-
thetic analogues; L. infantum to temporin 1Sa; L.donovani to 
bombinin H2 and H4, and to temporin A and B [31, 32].  
  A second mechanism of action of AMPs involves the 
recognition of intracellular targets. These peptides cross the 
plasma membrane without permanently harming it, and rec-
ognize intracellular targets such as DNA (buforin), DnaK 
chaperone (drosocin and phyrrhocorrycin), and mitochondria 
(histatin 5) [33]. Histatin 5 is a human salivary AMP that 
targets fungal mitochondria and is also active against 
Leishmania, in which it induces a decrease of mitochondrial 
ATP synthesis ending in cell death [33]. This molecule is 
considered very interesting because it behaves as a true cell-
penetrating peptide (a class of peptides more extensively 
treated below) that can be exploited to ferry a wide variety of 
cargo molecules (peptides, proteins, nucleic acids, and even 
nanoparticles) across the cell membrane [33]. Among AMP 
advantages we can list their rapid action against a broad 
spectrum of pathogens and their low tendency for resistance 
development, but their practical use is limited by serious 
drawbacks concerning difficult synthesis, metabolic stability, 
immunogenicity, bioavailability, route of administration, and 
production cost [34]. Most of these disadvantages are related 
to AMP large size, so the research in this field is currently 
devoted to design and develop smaller synthetic pepti-
domimetics [34-36]. 
NEW APPROACHES 
  Whereas traditional methods to generate genetic knock-
outs in protozoa are time-consuming, RNA interference 
(RNAi) can easily inhibit the expression of a target gene 
even if it is present in multiple copies, and as such is a sim-
pler and faster method to achieve genetic turn off. The ex-
ploitation of this technique allowed the discovery of hun-
dreds of host genes not previously known to be involved in 
host-pathogen interactions [37]. By now RNAi is extensively 
used to probe for protein functions [38, 39], to validate new 
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in T. brucei [41]. RNAi has been also used to elucidate the 
mechanisms that allow L. donovani survival inside phago-
cytic cells [42], and to investigate the genetic base of resis-
tance to malaria parasites in different anopheles strains [43].  
  Beyond its function as a valuable tool for gene function 
analysis, it can be envisaged that RNAi could be exploited 
for therapeutic purposes by directly inhibiting parasite gene 
expression with small interfering iRNAs (siRNAs) used as 
drugs. The introduction of a specific double stranded RNA 
into T. brucei by electroporation triggered a transient spe-
cific silencing of a cognate gene [44]. By the use of an inte-
gratable vector containing a tetracycline-inducible promoter 
and a DNA sequence producing dsRNA as a stem-loop 
structure, Wang et al. obtained a stably maintained inhibition 
of T. brucei gene expression [45], whereas Claser et al. by 
RNAi-mediated silencing of cytoketarin 18 gene inhibited T. 
cruzi intracellular replication [46].  
  The major limitation to the clinical application of RNAi 
is the poor permeability of cell membranes to negatively 
charged nucleic acids. To circumvent this problem, research 
has focused on the development of efficient delivery strate-
gies, of which one of the most promising seems the nanovec-
tor-based technique. Recently Aouadi M et al. demonstrated 
that in mice it is possible to target macrophages by orally 
delivering siRNAs encapsulated in glucan nanoparticles, 
obtaining a significant suppression of LPS-induced TNF- 
production [47]. A second siRNA delivery technique ex-
ploits the carrier capacities of cell-penetrating peptides 
(CPPs) [48]. The existence of CPPs, also referred to as pro-
tein transduction domains, was inferred from the observation 
that the HIV-1 Tat-protein was able to cross the plasma 
membrane by itself [49, 50]. Thereafter, a wide variety of 
CPPs derived from natural proteins have been discovered, 
and many others have been designed [51]. So far, CPPs can 
be grouped into two classes, of which the first requires cova-
lent linkage with the transported drug and has been validated 
for protein and peptide delivery, whereas the second, involv-
ing the formation of stable but non covalent linkages with 
the drug, allowed the introduction of oligonucleotides and 
siRNAs on preclinical states [52]. The CPP-based strategy 
has several advantages, including rapid and highly efficient 
intracellular delivery, stability of the complex in serum and 
physiological buffers, and lack of toxicity. Beyond the com-
mon CPP ability to deliver intracellular drugs with no mem-
brane damage, some peptides such as pVEC and TP10 pos-
sess direct antimicrobial activity against Candida albicans, 
Staphylococcus aureus and Mycobacterium smegmatis [53]. 
More recently Arrighi et al. demonstrated that TP10 is active 
against the blood and mosquito stages of P. falciparum and 
against the blood stage of T. brucei brucei [54].  
  The trypanosomatid genome sequentiation boosted the 
use of proteome-based techniques, that markedly contribute 
to our understanding of parasite biology, host-parasite inter-
actions, and drug action mechanisms. For most antimalarial 
drugs, neither mode of action nor mechanisms of resistance 
development are fully elucidated, although these would be 
important prerequisites for successfully developing urgently 
required novel antimalarials [55]. The mechanisms underly-
ing P. falciparum drug resistance have been investigated by 
analyzing the protein expression changes in trophozoites 
following treatment with cloroquine and artemisine [55]. 
These experiments were set up to develop a large-scale quan-
titative proteomic approach to study cellular responses to 
drug pressure, and allowed the preliminary identification of 
two sets of proteins up- and down-regulated in treated para-
sites.  
 The  T. brucei dominant factor responsible for resistance 
to the trypanolytic activity of human serum has been identi-
fied as a protein named SRA for Serum Resistance-
Associated [56]. This protein is a truncated version of the 
VSG (the parasite variant surface glycoprotein) and is lo-
cated in the endosomes, where it neutralizes human apolipo-
protein L1, a factor that induces parasite death by osmotic 
effect. Experiments performed in mouse models of T. brucei 
infection have shown that the injection of a conjugate com-
bining the pore-forming domain of apoL1 with the antigen-
binding region of a specific camelid antibody can block the 
course of infection [57]. Proteomic screen techniques are 
also very useful to identify proteins responsible for resis-
tance to in-use drugs. For example, El Fadili et al. observed 
that the expression of argininosuccinate synthetase (ARGG) 
was increased in a drug-resistant strain of L. infantum, 
whereas a decrease in the expression of the kinetoplastid 
membrane protein (KMP-11) correlated with the drug resis-
tance phenotype [58]. 
  Apart from the discovery of new drugs prompted by the 
identification of new targets, promising new fields of anti-
parasitic research are the approaches aimed to bring the drug 
directly and efficiently to the target pathogen. Drug chemis-
try alone is often not sufficient to fulfil this task, especially 
when the parasite localizes within organs, tissues or cells that 
behave as chemical or physical barriers to drug diffusion. 
Low efficiency of drug targeting requires higher dosages, 
and is considered one of the main causes of the serious side 
effects observed with most currently used antiparasitic drugs 
[59].  
  Novel formulation approaches involve the use of mi-
croparticles, nanoparticles, liposomes, niosomes or micro-
emulsions. The polyene antibiotic amphotericin B (AmB), 
isolated in 1955 from Streptomyces nodosus, has a notable 
effect against Leishmania, but due to its toxicity it is used as 
a second-line treatment for emerging strains resistant to first-
line products [60].  
  In the last decade AmB has been considered as a model 
for drug targeting and has been tried in many drug-carrier 
systems. Toxicity reduction has been achieved by the use of 
vehicles as lipid emulsions and unilamellar liposomes, some 
of which are presently in use [61]. However, the need of 
intravenous administration, stability and storage problems, 
and especially the high cost (that for some formulations is 
estimated to surpass one thousand dollars per patient per 
day) preclude their widespread use in developing countries 
[60]. Nanosized carriers are receiving special attention with 
the aim to improve drug bioavailability and selectivity, and 
some of them have already proved their effectiveness in the 
treatment and prophylaxis of malaria in animal models [62]. 
Basu and Lala prepared niosomes, non-ionic surfactant vesi-
cles with a retention capacity higher than that of liposomes, 
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and  in vivo tests [63]. The same and other Authors also 
tested different delivery systems for an unsaturated triterpene 
acid isolated from Mimusops elangii [64]. The nanoparticu-
late form has reduced hepatotoxicity and nephrotoxicity and 
may be considered useful for clinical applications in human 
leishmaniasis. Similarly, an indolizine compound linked to 
phospholipid microspheres was found active in experimental 
leishmaniasis [65], and the nanocapsulated quercetin resulted 
less toxic and more potent in reducing the Leishmania bur-
den in a hamster infection model [66]. Albumin microcap-
sules, that have been already validated as octafluoropropane 
carriers to enhance contrast in ultrasound imaging, represent 
an alternative that, as well as liposomes, selectively target 
macrophages. The encapsulation of AmB in albumin mi-
croparticles is cheap, and reduced toxicity improving AmB 
efficacy in vitro [60] and in a hamster model of L. infantum 
infection [67].  
  Recently, new inorganic materials with a porous structure 
that can be modified to control the drug release rate have 
been identified. These carriers are non toxic, biocompatible, 
and with a higher chemical and mechanical stability than 
organic vectors. Silica-based ordered mesoporous materials 
(i.e. materials that possess pores with diameters between 2 
and 50 nm) offer the advantage that the channels used as 
reservoirs to store drugs and biomolecules can be opened 
and closed at will by stimuli such as heat, pH, light, chemi-
cals, ultrasounds or magnetism [68]. So far, mesoporous 
materials have been tested as controlled delivery systems of 
antibiotics (amoxicillin, gentamicin and erythromycin) [68], 
and of antifungal drugs (ketoconazole, griseofulvin and itra-
conazole) [69]. With in vivo experiments on rabbits and 
dogs, Maellaerts et al. demonstrated that the systemic avail-
ability of itraconazole was significantly boosted when the 
drug was loaded into SBA-15, a mesoporous silicate that 
enhances the dissolution of drugs poorly soluble in water 
[70].  
CONCLUSIONS 
  Modern drug discovery relies on different, highly sophis-
ticated and complementary strategies that are very costly. 
The interaction between academic laboratories and lead dis-
covery departments of private companies [71], coupled with 
new funding sources and non-for-profit partnership, is cru-
cial to identify new active compounds [72]. Computer-
assisted drug design based on large molecular databases of 
compounds and targets are making in silico approaches like 
virtual screening by molecular docking more and more effi-
cient and cost-effective [73]. In vitro experiments based on 
the modelling results are already underway [74].  
  The identification of new targets and active compounds 
is rapidly progressing, but it is not expected to meet the ther-
apy needs in the close future. Therefore the short-term avail-
ability of new antiprotozoan drugs more reasonably relies on 
the development of already existing drugs, as is the case of 
ferroquine, an organometallic molecule that can overcome P. 
falciparum resistance to chloroquine and has entered phase 
IIb clinical trials in 2007 [75], or on the optimization of al-
ready in use effective drugs, as could be the case of antimo-
nials in leishmaniasis. In this field, new perspectives are of-
fered by the proven activity of orally administered meglu-
mine antimoniate-b-cyclodestrin conjugates [76], and by the 
development of a new liposome formulation of meglumine 
antimoniate, that in a dog infection model was effective at a 
20-fold-lower cumulative dose of Sb than is used for con-
ventional antimonial treatment [77]. A third possibility is the 
cooptation of drugs already developed for other pathologies, 
as has been the case of miltefosine, an anticancer agent 
originally used for the local treatment of skin metastases and 
now also marketed for its high activity against L. donovani. 
Similarly, a new molecule now in phase III anticancer clini-
cal trial, tipifarnib, is also currently being developed to be 
used against T. cruzi [78].  
  New developments are also involving the design of pre-
licensure phase III antimalarial trials: from tests aimed to 
assess the “superiority” of investigational products against 
the best in-use drugs, it has recently been recommended to 
shift to “non-inferiority” study design, in which the new 
therapy is deemed acceptable if it performs “at least as well 
as” a currently approved therapy [79]. This change should 
allow the licensing of a greater number of new antimalarials, 
that could minimize the global impact of resistance to artem-
isin combination therapy, should it arise.  
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